Table 2.
Frontline treatment responses in patients with stage IIIb AL amyloidosis
| Time from treatment initiation (n = 141) |
||||
|---|---|---|---|---|
| 1 mo | 3 mo | 6 mo | Best response | |
| Hematologic | ||||
| CR | 0 (0%) | 12 (9%) | 22 (15%) | 27 (19%) |
| VGPR | 42 (30%) | 36 (25%) | 28 (20%) | 26 (18%) |
| PR | 20 (14%) | 24 (17%) | 24 (17%) | 21 (15%) |
| ORR (≥PR) | 62 (44%) | 72 (51%) | 74 (52%) | 74 (52%) |
| Cardiac | ||||
| CR | 0 (0%) | 0 (0%) | 0 (0%) | 10 (7%) |
| VGPR | 1 (1%) | 2 (1%) | 12 (9%) | 14 (10%) |
| PR | 2 (1%) | 26 (19%) | 24 (17%) | 13 (9%) |
| ORR (≥PR) | 3 (2%) | 28 (20%) | 36 (26%) | 37 (26%) |
| CHCR | ||||
| Score 0-2 | 21 (15%) | 51 (36%) | 54 (38%) | 55 (39%) |
| Score 3-4 | 120 (85%) | 90 (64%) | 87 (62%) | 86 (61%) |
Responses were assessed on an intention-to-treat basis. One patient who had OHT followed by HDM/SCT as frontline treatment was excluded from response assessment. The CHCR was calculated by combing scores of 0 to 3 for hematologic response (0, CR; 1, VGPR; 2, PR; 3, NR) and 0 to 1 for cardiac response (0, cardiac response; 1, no cardiac response).
HDM/SCT, high-dose melphalan and autologous stem cell transplantation; ORR, overall response rate.